The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy

Frontiers in Cellular and Infection Microbiology

Volumn 4, Issue JUN, 2014, Pages

  Hamblin, Karleigh A ^a   Wong, Jonathan P ^b   Blanchard, James D ^c   Atkins, Helen S ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c ARADIGM CORPORATION   (United States)

Author keywords

Ciprofloxacin; Francisella tularensis; Liposomal; Tularemia

Indexed keywords

CIPROFLOXACIN; LIPOSOME; LIVE VACCINE; PLACEBO; ANTIINFECTIVE AGENT; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL STRAIN; BRONCHIECTASIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERANCE; ENCAPSULATION; FRANCISELLA TULARENSIS; HUMAN; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; SHORT SURVEY; STEADY STATE; TREATMENT OUTCOME; TULAREMIA; ANIMAL; DISEASE MODEL; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LIPOSOMAL; REVIEW;

CIPROFLOXACIN; FRANCISELLA TULARENSIS; LIPOSOMAL; TULAREMIA;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; LIPOSOMES; TREATMENT OUTCOME; TULAREMIA;

EID: 84907181983     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2014.00079     Document Type: Short Survey

References (20)

1. Brechner, R., DiFerdinando, G., Bresntiz, E., Factor, S. H., Matte, T. D., Siegel, L., et al. (2001). Update: adverse events associated with anthrax prophylaxis among postal employees-New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001. JAMA. 286, 2935-2936. doi: 10.1001/jama.286.23.2935
2. Bruinenberg, P., Blanchard, J., Cipolla, D., Dayton, F., Mudumba, S., and Gonda, I. (2010). "Inhaled liposomal ciprofloxacin: once a day management of respiratory infections," in Proceedings of Respiratory Drug Delivery, Vol. 1, eds R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, S. J. Farr, and P. M. Young (River Grove, IL), 73-82.
3. Celebi, G., Baruonu, F., Ayoglu, F., Cinar, F., Karadenizli, A., Ugur, M. B., et al. (2006). Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses. Jpn. J. Infect. Dis. 59, 229-234.
4. Cipolla, D., Dayton, F., Fulzele, S. V., Gabatan, E., Mudumba, S., Wu, H., et al. (2010). "Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance," in Proceedings of Respiratory Drug Delivery, Vol. 2, eds R. N. Dalby, P. R. Byron, J. Peart, J. D. Suman, S. J. Farr, and P. M. Young (River Grove, IL), 409-414.
5. Conley, J., Yang, H. M., Wilson, T., Blasetti, K., Di Ninno, V., Schnell, G., et al. (1997). Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 41, 1288-1292.
6. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., et al. (2001). Tularemia as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285, 2763-2773. doi: 10.1001/jama.285.21.2763
7. Di Ninno, V. L., Cherwonogrodzky, J. W., and Wong, J. P. (1993). Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis. J. Infect. Dis. 168, 793-794. doi: 10.1093/infdis/168.3.793
8. Hamblin, K. A., Armstrong, S. J., Barnes, K. B., Davies, C., Wong, J. P., Blanchard, J. D., et al. (2014). Liposome-encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis Schu S4 strain. Antimicrob. Agents Chemother. 58, 3060-3072. doi: 10.1128/AAC.02555-13
9. Hepburn, M. J., and Simpson, A. J. H. (2008). Tularemia: current diagnosis and treatment options. Expert Rev. Anti Infect. Ther. 6, 231-240. doi: 10.1586/14787210.6.2.231
10. LeBel, M., Bergeron, M. G., Vallée, F., Fiset, C., Chassè, G., Bigonesse, P., et al. (1986). Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob. Agents Chemother. 30, 260-266. doi: 10.1128/AAC.30.2.260
11. Lettieri, J. T., Rogge, M. C., Kaiser, L., Echols, R. M., and Heller, A. H. (1992). Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36, 993-996. doi: 10.1128/AAC.36.5.993
12. Meric, M., Willke, A., Finke, E. J., Grunow, R., Sayan, M., Erdogan, S., et al. (2008). Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. Apmis 116, 66-73. doi: 10.1111/j.1600-0463.2008.00901.x
13. Perez-Castrillon, J. L., Bachiller-Luque, P., Martin-Luquero, M., Mena-Martin, F. J., and Herreros, V. (2001). Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis. 33, 573-576. doi: 10.1086/322601
14. Piercy, T., Steward, J., Lever, M. S., and Brooks, T. J. G. (2005). In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J. Antimicrob. Chemother. 56, 1069-1073. doi: 10.1093/jac/dki359
15. Pinto-Alphandary, H., Andremont, A., and Couvreur, P. (2000). Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13, 155-168. doi: 10.1016/S0924-8579(99)00121-1
16. Serisier, D. J. (2012). Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today 48, 339-351. doi: 10.1358/dot.2012.48.5.1789474
17. Serisier, D. J., Bilton, D., De Soyza, A., Thompson, P. J., Kolbe, J., Greville, H. W., et al. (2013). Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 68, 812-817. doi: 10.1136/thoraxjnl-2013-203207
18. Steward, J., Piercy, T., Lever, M. S., Simpson, A. J. H., and Brooks, T. J. G. (2006). Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents 27, 439-443. doi: 10.1016/j.ijantimicag.2006.02.006
19. Wong, J. P., Cherwonogrodzky, J. W., Di Ninno, V., Dela Cruz, R., and Saravolac, E. G. (1995). "Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases by intracellular pathogens," in Liposomes in Biomedical Applications, ed P. N. Shek (Amsterdam: Harwood Academic Press), 105-120.
20. Wong, J. P., Yang, H. M., Blasetti, K. L., Schnell, G., Conley, J., and Schofield, L. N. (2003). Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92, 265-273. doi: 10.1016/S0168-3659(03)00358-4